DFX Intelligence

R. Jacob Vogelstein

Co-Founder & Managing Partnerat Catalio Capital Management, LP· New York, NY

As of 2026-10-01 · this person's identity; each section below carries its own date

Current roles: 1
Investments attributed: 7
Board seats: 3

Ask DFX about this View relationships Find contacts Investments Board seats

As of 2026-10-01 · this person's identity; each section below carries its own date

10 additional roles and seats, 4 additional attributed investments

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

2 deals
12 months
2 investments attributed in the last 12 months;
A partner with a recent deal is actively writing cheques now.
Factfunding announcements and Form D naming the personFor Founders, co-investorsInvestments →

Relationship network

17 connected entities7 observed investment recordsinvestment records 2019 to 2026

From the roles sources name this person in, the investments a source attributes to them, and the boards and funds Form D names them on.

Some relationships on this record are counted rather than named here. They open with the full profile.

Click any name or line for the investment records and sources behind it. Line weight is investment records together; dashed lines are inferred.

Reading the network

Organization
Company
Fund or vehicle

›How strength and recency are read

Venture relationships are not scored. Each line names its claim: a round led or joined, a board seat or a filing that names the firm, a listing on a portfolio page (dated by when DFX saw it, never by when the investment was made), a disclosed LP commitment, or a co-investor pair counted from observed participations. Observed means a named source says so; Derived means DFX counted it from observed rows; Inferred means a match that may be wrong.

Darker lines were active in the last 24 months or are current; lighter lines are older or undated.

Ask DFX about this network

Which companies and boards is R. Jacob Vogelstein connected to?

How am I connected?

Name your firm, a company or a person, and DFX finds the published routes to R. Jacob Vogelstein: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.

See how you connect to R. Jacob Vogelstein

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

Drawing the relationship network…

Roles

1 current, 0 past

Catalio Capital Management, LP Co-Founder & Managing Partner
? to present · “team page: R. Jacob Vogelstein / Co-Founder & Managing Partner”
Fact Firm website

Investments attributed to this person

Company	Round	Investor	Attribution	Date	Source
NextPoint Therapeutics, Inc.	board only	Catalio Capital Management, LP	strongly supported · board	Jul 30, 2026	Inference sec.gov
Pheast Therapeutics, Inc.	Form D equity offering · $24.6M	Catalio Capital Management, LP	strongly supported · board	Oct 16, 2025	Inference sec.gov
NextPoint Therapeutics, Inc.	Form D equity offering · $42.5M	Catalio Capital Management, LP	strongly supported · board	Feb 14, 2024	Inference sec.gov

Board seats and vehicles

3 boards, 13 vehicles

NextPoint Therapeutics, Inc. Director Jul 30, 2026 Inference
Pheast Therapeutics, Inc. board seat on a deal Oct 16, 2025 Inference
eNeura board seat on a deal Feb 21, 2020 Inference
Catalio Access Fund XI, LLC Executive Officer Jul 8, 2026
Catalio Access Fund IX, LLC Executive Officer Jul 8, 2026
Catalio Access Fund XII, LLC Executive Officer Sep 10, 2026

Timeline

3 dated entries: events, attributed deals, board seats and role changes

Jul 30, 2026
Board seat at NextPoint Therapeutics, Inc. (Catalio Capital Management, LP)
Board seat Inference NextPoint Therapeutics, Inc. Form D
Oct 16, 2025
Form D equity offering in Pheast Therapeutics, Inc. (Catalio Capital Management, LP)
Attributed investment Inference Pheast Therapeutics, Inc. Form D
Feb 14, 2024
Form D equity offering in NextPoint Therapeutics, Inc. (Catalio Capital Management, LP)
Attributed investment Inference NextPoint Therapeutics, Inc. Form D